The IL-15–AKT–XBP1s signaling pathway contributes to effector functions and survival in human NK cells
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The IL-15–AKT–XBP1s signaling pathway contributes to effector functions and survival in human NK cells
Authors
Keywords
-
Journal
NATURE IMMUNOLOGY
Volume 20, Issue 1, Pages 10-17
Publisher
Springer Nature
Online
2018-11-28
DOI
10.1038/s41590-018-0265-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival
- (2017) Charlotte Viant et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells
- (2016) Yufeng Wang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion
- (2016) D. Gotthardt et al. Cancer Discovery
- ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
- (2015) Juan R. Cubillos-Ruiz et al. CELL
- Transcription Factor Foxo1 Is a Negative Regulator of Natural Killer Cell Maturation and Function
- (2015) Youcai Deng et al. IMMUNITY
- The transcription factor XBP1 is selectively required for eosinophil differentiation
- (2015) Sarah E Bettigole et al. NATURE IMMUNOLOGY
- Phosphorylation and activation of ubiquitin-specific protease-14 by Akt regulates the ubiquitin-proteasome system
- (2015) Daichao Xu et al. eLife
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
- (2014) J. Chu et al. CLINICAL CANCER RESEARCH
- Endoplasmic Reticulum Stress Regulator XBP-1 Contributes to Effector CD8+ T Cell Differentiation during Acute Infection
- (2014) D. Kamimura et al. JOURNAL OF IMMUNOLOGY
- XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway
- (2014) Xi Chen et al. NATURE
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- The Critical Role of IL-15–PI3K–mTOR Pathway in Natural Killer Cell Effector Functions
- (2014) Neethi Nandagopal et al. Frontiers in Immunology
- Unspliced XBP1 controls autophagy through FoxO1
- (2013) Rene L Vidal et al. CELL RESEARCH
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- NK cell cytotoxicity mediated by 2B4 and NTB-A is dependent on SAP acting downstream of receptor phosphorylation
- (2013) Stephan Meinke et al. Frontiers in Immunology
- The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule
- (2012) B. C. S. Cross et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Heightened Induction of Proapoptotic Signals in Response to Endoplasmic Reticulum Stress in Primary Fibroblasts from a Mouse Model of Longevity
- (2011) Amir A. Sadighi Akha et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- HSP72 Protects Cells from ER Stress-induced Apoptosis via Enhancement of IRE1α-XBP1 Signaling through a Physical Interaction
- (2010) Sanjeev Gupta et al. PLOS BIOLOGY
- Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion
- (2009) B. Jahrsdorfer et al. BLOOD
- Preventing oxidative stress: a new role for XBP1
- (2009) Y Liu et al. CELL DEATH AND DIFFERENTIATION
- Unconventional splicing of XBP1 mRNA occurs in the cytoplasm during the mammalian unfolded protein response
- (2009) A. Uemura et al. JOURNAL OF CELL SCIENCE
- Leukemic challenge unmasks a requirement for PI3K in NK cell-mediated tumor surveillance
- (2008) E. Zebedin et al. BLOOD
- The p110δ of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation
- (2008) Hailong Guo et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started